What is HCA Healthcare's current analyst consensus after the downgrades?

Despite multiple price target cuts, the analyst consensus remains Overweight/Outperform with a mean target of approximately $519–$551, implying significant upside from the current price of $442.51.

Which other analysts cut HCA Healthcare targets at the same time?

RBC (to $534), Oppenheimer (to $520), Wells Fargo (to $436), and Jefferies (to $525) all cut targets alongside KeyBanc, with Jefferies citing weather-related volume impacts.

Does the HCA earnings miss affect other hospital stocks?

Yes — hospital peers like Tenet Healthcare Corporation face sympathy risk as they share the same utilization-trend fundamentals. Sector-wide healthcare ETFs may also see mild bearish pressure.

Is HCA Healthcare stock a buy after the price target cuts?

Analysts maintain Buy/Overweight ratings with 17–24% upside to consensus targets, but short-term momentum is negative. Traders should monitor volume confirmation and earnings guidance before establishing long positions.

Quick Links

KeyBanc Slashes HCA Healthcare Target to $510 Amid Broad Analyst Downgrades After Weak Quarter

Published: 2026-04-27 14:24:09 UTC

View HCA Page

Data Snapshot

Price

$441.94

24h Low

$434.38

24h High

$445.35

24h Change

+2.17%

24h Change (%)

+2.04%

KeyBanc New PT

$510 (from $550)

HCA Current Price

$442.51

Analyst Consensus Mean PT

$519–$551

Key Takeaways

•KeyBanc cut HCA's price target from $550 to $510; at least 5 major firms revised targets lower simultaneously, signaling broad earnings disappointment.
•HCA's current live price of $442.51 sits well below the analyst consensus target of ~$519–$551, implying 17–24% upside but with negative short-term momentum.
•Weather-related volume headwinds (cited by Jefferies) and post-COVID utilization normalization are the key fundamental drivers of the weak quarter.
•Sector peers including Tenet Healthcare and UnitedHealth Group face sympathy risk; monitor hospital utilization data as a leading indicator.
•Despite the downgrades, all cutting analysts maintained Buy/Overweight ratings — this is a valuation recalibration, not a thesis abandonment.

HCA Healthcare, Inc. (NYSE: HCA) — the largest U.S. private hospital operator with 190 hospitals and 121 surgery centers — has drawn a wave of analyst price target cuts following a disappointing quart

Event Analysis

HCA Healthcare, Inc. (NYSE: HCA) — the largest U.S. private hospital operator with 190 hospitals and 121 surgery centers — has drawn a wave of analyst price target cuts following a disappointing quarterly performance. As reported by Futunn and MarketScreener, KeyBanc Capital Markets reduced its price target from $550 to $510 (a ~7.3% cut) while maintaining its Overweight rating. The action was far from isolated: RBC cut from $593 to $534, Oppenheimer from $540 to $520, Wells Fargo from $481 to $436, and Jefferies from $590 to $525 — the latter citing weather-related volume headwinds.

What makes this cycle of cuts notable is the breadth and simultaneity. Multiple bulge-bracket and mid-tier firms adjusting targets in lockstep signals more than a one-off miss — it points to a structural softness in hospital utilization trends. Jefferies' specific callout of weather impact suggests Q1 2026 volumes were depressed by external factors, but the scale of revisions implies underlying demand normalization is also at play as post-COVID healthcare catch-up volumes continue to fade. This is an earnings miss revenue shock pattern that warrants monitoring across the hospital sector.

Despite the cuts, consensus remains constructive. According to ValueInvesting.io and TickerNerd, the mean analyst price target sits at approximately $519–$551, implying 17–24% upside from HCA's current live price of $442.51. The Overweight/Outperform consensus from 25–45 analysts remains intact, suggesting this is a valuation reset rather than a thesis break. The gap between analyst targets and current price means HCA could attract dip buyers, but near-term momentum remains negative given the cadence of revisions. Traders can explore the broader healthcare sector context via the 2026 Stocks Market Outlook.

What This Means for Traders

For short-term traders, the directional bias on HCA CFDs is cautiously bearish. The stock is currently trading at $442.51 (live data), with a 24-hour range of $434.38–$445.35. Despite a +2.17% intraday recovery, the barrage of PT cuts creates overhead resistance and may suppress any sustained rally until earnings guidance is clarified. Watch for volume confirmation — a break below $434 could open the door toward the $420s, while reclaiming $450 sustainably would signal sentiment stabilization. Check open interest and funding rates on CoinUnited.io for directional confirmation before entering positions.

Sector contagion is a secondary concern. Tenet Healthcare Corporation and UnitedHealth Group Incorporated face sympathy pressure as hospital utilization data is a shared fundamental. Broader S&P 500 Index and NASDAQ 100 Index exposure is limited given healthcare's sector-specific dynamics, but a sustained drawdown in large-cap healthcare names can contribute to mild risk-off sentiment in defensive portfolios. Traders with healthcare sector exposure should review the complete guide to trading sectors across markets for context on how sector-wide earnings trends affect positioning strategy.

Trade HCA Healthcare, Inc. on CoinUnited.io

Trade HCA with up to 800xx leverage → | Create Free Account

Frequently Asked Questions

KeyBanc reduced its price target from $550 to $510 following a weak quarterly performance by HCA Healthcare, reflecting disappointing hospital utilization volumes. The firm maintained its Overweight rating, signaling the cut is a recalibration rather than a bearish stance shift.